Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04223869
Other study ID # 2014-106-03/06
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2015
Est. completion date May 2017

Study information

Verified date January 2020
Source Bulent Ecevit University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to 1) identification of the impact of IL-34 on the pathogenesis of periodontal disease and determine whether any relationship among the existing levels of Gingival crevicular fluid (GCF) Interleukin 34( IL-34 )and GCF Receptor activator of nuclear factor -kB ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio, as a mediator of bone resorption 2) analysis of the impact of non-surgical periodontal treatment on GCF IL-34 levels in patients with chronic periodontitis (CP) and aggressive periodontitis (AgP) and 3) to correlate between biochemical markers and clinical recordings


Description:

A novel cytokine interleukin 34 (IL-34) is a second possible functional ligand of macrophage colony-stimulating factor-1 receptor (CSF-1R). IL-34 is secreted in different tissues including: heart, brain, lung, liver, kidney, thymus, testes, ovary, small intestine, prostate, colon and spleen . IL-34 shares vital functions of macrophage colony-stimulating factor -1(CSF-1), and manage myeloid cell survival, differentiation and proliferation. It is produced by synovial fluid, gingival fibroblast and human adipose tissue, and is controlled by the transcription factor RANK and activation of c-Jun N-terminal kinase (CJNK). Additionally, the pro-inflammatory cytokines tumornecrosis factor-alfa (TNF-α) and interleukin-1beta (IL-1β) arrange IL-34 release from gingival fibroblasts, by a mechanism including nuclear factor -kB (NF-kB) and mitogen activated protein kinase (MAPK).The targeting CSF-1 merely is not adequate to inhibit the effect via CSF-1R. Moreover, neither RANKL nor IL-34 solely can cause osteoclast formation which suggests that IL-34 is required but not enough. IL-34 plays a crucial role in RANKL-induced osteoclastogenesis; the osteoclasts differentiation is mediated by the same way with CSF-1.

Several studies evaluated the role of IL-34 in the pathogenesis of chronic periodontitis (CP). To the best of our knowledge, any of these studies reported the relationship between GCF IL-34 level and GCF RANKL/OPG ratio in other types of periodontitis before and after non-surgical periodontal therapy. This study highlights the influence of IL-34 in the pathogenesis of Chronic Periodontitis (CP) and Aggressive Periodontitis (AgP).

The objective of this study is to 1) identification of the impact of IL-34 on the pathogenesis of periodontal disease and determine whether any relationship among the existing levels of GCF IL-34 and GCF RANKL, OPG and RANKL/OPG ratio, as a mediator of bone resorption 2) analysis of the impact of non-surgical periodontal treatment on GCF IL-34 levels in patients with CP and AgP and 3) to correlate between biochemical markers and clinical recordings.

The study included 60 subjects: 20 who were periodontally healthy (CTRL), 20 with chronic periodontitis (CP)and 20 with aggressive periodontitis (AgP). Patients with periodontitis were treated with non-surgical periodontal therapy. GCF sampling procedures and clinical periodontal measures were investigated at the baseline and 6 weeks after treatment. Levels of IL-34, RANKL and OPG were analyzed with Enzyme-linked immunosorbent assay (ELISA).

Participants were periodontally assessed at baseline and after non-surgical periodontal therapy in accordance with the following criteria; plaque index (PI)(Silness and Loe, 1964), GI(Loe and Silness, 1963), PPD, clinical attachment level (CAL) and BOP (judged positive if it developed within 15 s following contact). Full-mouth periapical radiographs were used to determine the periodontal bone loss.The clinical measurement were taken in millimeters by a single calibrated examiner (ŞBD), who was blinded to the whole study composition, from six locations of each tooth (mesio-buccal, disto-buccal, mid-buccal, mesiolingual, disto-lingual, and mid-lingual), by the use of a periodontal probe (Hu-Friedy, Chicago, IL, USA).

Two sites per participant were selected to collect GCF for each group. GCF samples were collected from the mesiobuccal or distobuccal sites of single-rooted teeth. The sample areas were isolated with cotton rolls, saliva contamination was ensured, all supragingival plaque was eliminated by sterile curette and it was slightly air dried. The paper strips were inserted within the crevice until resistance was encountered and then allowed to remain in place for 30 seconds. The amount of GCF on the strips was measured by weighing the collected liquid. The strips were placed into closed and numbered plastic eppendorf tubes. The liquid was weighed again, immediately after collection, to take into account evaporation. The samples consisting of saliva and blood were discarded from the study. Two available for use samples from per individual were merged to make a singular sample and instantly insert in a singular Eppendorf tube and freezed at _80°C until aftertime evaluation.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date May 2017
Est. primary completion date February 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 55 Years
Eligibility Inclusion Criteria:

- CP group included 20 patients, = 35 years of age, and this category was displayed as a minimum of six teeth available clinical attachment loss (AL) and pocket probing depth (PPD) = 5mm. These teeth exhibited positive bleeding on probing (BOP) across a minumum 2 separate quadrants and bone loss affecting >30 % of available teeth on clinical and radiographic inspection. The gingival index (GI) score for indications of inflammation (red color and edema of the gingival margin) was >1 for the CP group.

- AgP group included 20 patients, <35 years of age, and cases showed PPD= 5mm with at least six teeth and radiographic evidence of alveolar bone loss. At least three of these six teeth with PPD = 5 mm were not molars or incisors. These patients showed severe periodontal tissue devastation and decrease of periodontal support conflicting with age and plaque levels.

- Control group included 20 participants and they presented PPD = 3mm, GI=0 (nonavailable of clinical inflammation), absence of alveolar bone loss (e.g., distance between the cemento-enamel junction and the bone crest was <3mm in> 95% of proximal tooth sites).

- All participants had minimum 20 teeth and their overall systematic health

Exclusion Criteria:

- lactation

- pregnancy

- current and ex-smoking habits

- undergone nonsurgical periodontal therapy and prescription of antibiotics or non-steroidal anti-inflammatory medication within the previous 6 months or surgical periodontal treatment within the preceding year

- postmenopause

- systemic conditions such as; diabetes mellitus, cancer, cardiovascular and respiratory diseases, rheumatoid arthritis, osteoporosis, or immunologic disorders, that might cause progress of periodontal disease.

Study Design


Intervention

Other:
non-surgical periodontal treatment
scaling and root planing were performed

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bulent Ecevit University

Outcome

Type Measure Description Time frame Safety issue
Primary gingival crevicular fluid IL-34 level gingival crevicular fluid IL-34 levels change from baseline to at 6th week 6th week
Secondary Gingival crevicular fluid RANKL level change of gingival crevicular fluid RANKL levels from baseline at 6th weeks 6th week
Secondary Gingival crevicular fluid OPG level change of gingival crevicular fluid OPG levels from baseline at 6th weeks 6th week
Secondary Plaque index oral hygiene score 6th week
Secondary Gingival index gingival inflammation score 6th week
Secondary bleeding on probing deemed positive if it occurred within 15 seconds after probing 6th week
Secondary clinical attachment level distance between the cemento-enamel junction to the deepest point of periodontal pocket 6th week
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06400069 - Role of NLRP6 in Chronic Periodontitis
Completed NCT05231096 - Comparison of the Effect of Gingival Massage of Aloe-vera Gel and Sidr Honey on Chronic Periodontitis N/A
Completed NCT03203746 - Gingival Crevicular Fluid Levels of Protein Carbonyl Following the Use of Lycopene in Chronic Periodontitis Phase 1/Phase 2
Active, not recruiting NCT03354338 - Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy Phase 2
Completed NCT02516111 - Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment Phase 2/Phase 3
Terminated NCT02568163 - Influence of Stress on Non Surgical Periodontal Treatment N/A
Completed NCT02174146 - Leptin and Visfatin in Diabetic Patients With Periodontitis Before and After Periodontal Therapy N/A
Completed NCT02430519 - Benefits of Platelet Rich Fibrin In Mandibular Molar Furcation Defects N/A
Completed NCT01438333 - Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection N/A
Completed NCT01233765 - Analysis of Neutrophil Response in Chronic Periodontitis N/A
Completed NCT02218515 - Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft Phase 4
Completed NCT02197260 - Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing Phase 4
Not yet recruiting NCT03270280 - Comparison of Salivary Interleukin-1β and Matrix Metalloproteinase-8 Levels in Individuals With Chronic Periodontitis Phase 2
Not yet recruiting NCT04026828 - Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods
Completed NCT04643288 - Nanocrystalline Hydroxyapatite Bone Substitute for Treating Periodontal Intrabony Defects N/A
Completed NCT04697199 - The Adjunctive Effect of Probiotics to Non Surgical Treatment of Chronic Periodontitis Phase 1
Completed NCT03039244 - Evaluation of Antimicrobial Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers N/A
Completed NCT02518152 - Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis Phase 2/Phase 3
Completed NCT02851823 - Combined Use of Er:YAG and Nd:YAG Laser N/A
Completed NCT03874390 - Effects of Ozone Therapy on Clinical Parameters and Inflammatory Cytokines in Chronic Periodontitis Patients N/A